Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,844.48 -32.57 (-0.41%) Bitcoin USD
65,310.12 +3,053.06 (+4.90%) CMC Crypto 200
1,343.47 +30.85 (+2.41%)
KALA BIO, Inc. (KALA)
After hours:
| Previous close | 6.83 |
| Open | 6.90 |
| Bid | 4.83 x 200 |
| Ask | 8.80 x 200 |
| Day's range | 6.66 - 6.90 |
| 52-week range | 5.10 - 19.35 |
| Volume | |
| Avg. volume | 21,546 |
| Market cap | 19.18M |
| Beta (5Y monthly) | -1.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -17.35 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.33 |
GlobeNewswireKALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceuti
- GlobeNewswire
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also
- GlobeNewswire
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually. A pre-recorded fireside chat will be made available beginning on Tuesday, February 13, 2024 at 12:00 p.m.
